ALung Technologies recently announced the initiation of patient enrollment in its VENT-AVOID trails with the Minneapolis Heart Institute Foundation. The trial is pivotal in validating the safety and efficacy of the Hemolung Respiratory Assist System for COPD patients who require ventilatory support.
Recent Posts
UPMC Enterprises announces $1 billion commitment to life sciences investments
The Translational Sciences team at UPMC Enterprises will be investing $1 billion by 2024 to develop new drugs, diagnostics, and devices.
Read More →
Meet the Executive: Wendy Zellner, Vice President of Public Relations at UPMC
At UPMC, Zellner helps to oversee UPMC’s roughly 15-person media group (covering UPMC and Pitt Schools of the Health Sciences), and personally works with UPMC’s Enterprises, International, Information Services, and Quality divisions to identify and tell the organizations’ best stories to the media.
Read More →